Aurobindo News

Lannett's Seymour manufacturing facility, an arm of Aurobindo, received four observations from the U.S. FDA.

The U.S. FDA has flagged the Hyderabad plant of Aurobindo's arm, indicating potential regulatory concerns.

The U.S. FDA has classified Aurobindo's North Carolina plant as Voluntary Action Indicated (VAI), allowing pending applications for inhalers and other dosage fo

Pharma stocks like Dr Reddy's, Aurobindo, and Cipla are in focus today following Donald Trump's new generic drugs tariff plan, which will impose significant dut

Shares of Sun Pharma, Aurobindo, Lupin, and Zydus Life are in focus following Trump's announcement of a two-year zero tariff policy on generics. US exports cons

CuraTeQ Biologics, a subsidiary of Aurobindo, has received approval from Brazil's health regulator, ANVISA, for its facility following a good manufacturing prac